149 related articles for article (PubMed ID: 38396679)
21. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
22. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
[TBL] [Abstract][Full Text] [Related]
23. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
24. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
25. Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Kadera BE; Toste PA; Wu N; Li L; Nguyen AH; Dawson DW; Donahue TR
Clin Cancer Res; 2015 Jan; 21(1):157-65. PubMed ID: 25348515
[TBL] [Abstract][Full Text] [Related]
26. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
[TBL] [Abstract][Full Text] [Related]
27. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
28. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
29. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
31. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
[TBL] [Abstract][Full Text] [Related]
32. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
33. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
35. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
[TBL] [Abstract][Full Text] [Related]
37. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
[TBL] [Abstract][Full Text] [Related]
38. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
39. Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Huang ZQ; Buchsbaum DJ; Raisch KP; Bonner JA; Bland KI; Vickers SM
J Surg Res; 2003 May; 111(2):274-83. PubMed ID: 12850474
[TBL] [Abstract][Full Text] [Related]
40. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
